GSK Vaccines Institute for Global Health srl., Siena, Italy.
Bill & Melinda Gates Foundation, 62 Buckingham Gate, London, United Kingdom; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Semin Immunol. 2020 Aug;50:101433. doi: 10.1016/j.smim.2020.101433. Epub 2020 Dec 9.
Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps.
近年来，外膜囊泡（OMV）作为一种针对细菌病原体的疫苗平台受到了越来越多的关注。B 群脑膜炎奈瑟菌的 OMV 已经得到了广泛的探索。在 MeNZB OMV 疫苗成功控制了新西兰 B 群脑膜炎奈瑟菌的爆发之后，进一步的研究和开发导致了含有 OMV 的四组分 4CMenB 疫苗 Bexsero 的许可。这为预防多种 B 群脑膜炎奈瑟菌菌株提供了更广泛的保护。基因工程领域的进步使得该平台得到了进一步的改进，提高了产量，降低了内毒素毒性，并通过同源和异源抗原的修饰来增强免疫原性，提供更广泛的保护。OMV 疫苗平台已经扩展到许多其他病原体。在这篇综述中，我们讨论了 OMV 疫苗传递平台的发展进展，强调了成功的应用，以及潜在的挑战和差距。
